Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 15/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763643 | 0.91 | CRBN (0.45) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL12593553 | 0.90 | NR3C1 (0.50) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL1763399 | 0.84 | SLC9A1 (0.54) | SLC9A1RBP4MEN1KMT2ACYP2C9 | |
| SCHEMBL7994436 | 0.82 | SLC9A1 (0.51) | SLC9A1RBP4MEN1KMT2ACYP2C9 | |
| SCHEMBL12593507 | 0.81 | CRBN (0.49) | NR3C1PGRSLC6A4KCNH2PDE3B | |
| SCHEMBL1763837 | 0.80 | SLC9A1 (0.50) | KCNH2SLC9A1RBP4CYP2C9CYP2C19 | |
| SCHEMBL1763883 | 0.79 | SLC9A1 (0.69) | KCNH2SLC9A1RBP4CYP2C9CYP2C19 | |
| SCHEMBL1763661 | 0.79 | SLC9A1 (0.58) | KCNH2SLC9A1RBP4MEN1KMT2A | |
| SCHEMBL1764148 | 0.76 | SLC9A1 (0.55) | SLC9A1RBP4MEN1KMT2ACYP2C9 | |
| SCHEMBL1763461 | 0.76 | SLC9A1 (0.55) | KCNH2SLC9A1RBP4KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | NR3C1 2474/4885PGR 2826/4885SLC6A4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.